🇺🇸 FDA
Patent

US 11617761

Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor

granted A61KA61K31/713A61K9/127

Quick answer

US patent 11617761 (Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor) held by The Regents of the University of California expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K31/713, A61K9/127, A61K9/14